DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Japan
  • /
  • Healthcare
Author Program NEWCreate Narrative
6869 logo

Sysmex Corporation Stock Price

TSE:6869 Community·JP¥1.1t Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 10 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

6869 Share Price Performance

JP¥1,859.50
-7.50 (-0.40%)
​
JP¥2,060.71
Fair Value
JP¥1,859.50
-7.50 (-0.40%)
9.8% undervalued intrinsic discount
JP¥2,060.71
Fair Value
Price JP¥1,859.50
AnalystConsensusTarget JP¥2,060.71
AnalystHighTarget JP¥2,967.29
AnalystLowTarget JP¥1,380.00
Thu, 17 Sep 26
Fair ValueJP¥2,060.71
Share Pricen/a

6869 Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value JP¥2.06k 9.8% undervalued intrinsic discount

Hemostasis Expansion And Value Chain Reforms Will Reshape Long Term Prospects

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value JP¥2.97k 37.3% undervalued intrinsic discount

Aging Demographics And Global Expansion Will Drive Long Term Diagnostic Demand

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value JP¥1.38k 34.7% overvalued intrinsic discount

Aging Diagnostics Demand Will Offset China Headwinds And Support Steady Long-Term Earnings

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
6869 logo
Sysmex
9.8% undervalued intrinsic discount
Updated

Hemostasis Expansion And Value Chain Reforms Will Reshape Long Term Prospects

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 17 Sep
Read Narrative
6869 logo
Sysmex
37.3% undervalued intrinsic discount

Aging Demographics And Global Expansion Will Drive Long Term Diagnostic Demand

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 3 Sep
Read Narrative
6869 logo
Sysmex
34.7% overvalued intrinsic discount

Aging Diagnostics Demand Will Offset China Headwinds And Support Steady Long-Term Earnings

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Published 21 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
6869 logo

6869: Collaboration, Guidance And Completed Buyback Will Support A Steady Outlook

Fair Value: JP¥2.06k 9.8% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
6869 logo

6869: Share Buybacks And Upgraded Earnings Guidance Will Support Stronger Returns

Fair Value: JP¥2.97k 37.3% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
6869 logo

Aging Diagnostics Demand Will Offset China Headwinds And Support Steady Long-Term Earnings

Fair Value: JP¥1.38k 34.7% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Excellent balance sheet established dividend payer.

1 Risk
3 Rewards
View Full Analysis

Sysmex Corporation Key Details

JP¥524.9b

Revenue

JP¥257.4b

Cost of Revenue

JP¥267.5b

Gross Profit

JP¥227.9b

Other Expenses

JP¥39.6b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 10, 2026
65.42
50.96%
7.54%
16.8%
View Full Analysis

About 6869

Founded
1968
Employees
10861
CEO
Hisashi Ietsugu
WebsiteView website
www.sysmex.co.jp

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers hematology, a major test routinely included in blood tests; Flow Cytometry (FCM) analyzes cell properties by irradiating individual cells with a laser and measuring the intensity of light scattering and fluorescence; urinalysis test checks for the presence of glucose, proteins, and blood in urine; clinical chemistry; hemostasis; immunochemistry; cancer gene testing; and antimicrobial susceptibility testing. The company also provides Caresphere, an ICT solution, which integrates and analyzes real time various data managed through testing instruments and clinical testing information systems, and supports the efficient operation of clinical laboratories; and involved in the medical robotics business. It serves products and services to medical institutions, clinical laboratories, animal hospitals, and research institutes. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.

Recent 6869 News & Updates

User avatar
Narrative Update • Sep 17

6869: Collaboration, Guidance And Completed Buyback Will Support A Steady Outlook

Analysts have raised their price target for Sysmex from ¥1,800 to about ¥2,060. They cited updated assumptions for revenue growth, profit margin and future P/E levels as key drivers of the change.

Recent updates

No updates

Sysmex Corporation Competitors

7741 logo

HOYA

Symbol: TSE:7741
Market cap: JP¥7.6t
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide